Literature DB >> 12791475

In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.

J C Rodriguez Díaz1, M López, M Ruiz, G Royo.   

Abstract

The objective of the study was to determine the activity of new fluoroquinolones and linezolid against 108 clinical isolates of different species of non-tuberculous mycobacteria isolated in Spain. Gatifloxacin and moxifloxacin were found to be more effective than levofloxacin. Mycobacterium kansasii was more susceptible to the fluoroquinolones tested than M. avium complex and M. fortuitum was more susceptible than M. chelonae. Linezolid was more active against M. kansasii than against M. avium complex. A better understanding of the relationship between the in vitro activity of these compounds and their usefulness in the treatment of these infections is needed. The new fluoroquinolones exhibit good activity against M. kansasii and M. fortuitum and linezolid is active against M. kansasii.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12791475     DOI: 10.1016/s0924-8579(03)00048-7

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  6 in total

1.  In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.

Authors:  Carmen A Molina-Torres; Jorge Ocampo-Candiani; Adrian Rendón; Michael J Pucci; Lucio Vera-Cabrera
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

2.  Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.

Authors:  Fernando Alcaide; Laura Calatayud; Miguel Santín; Rogelio Martín
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

3.  In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.

Authors:  Yoshihisa Kohno; Hideaki Ohno; Yoshitsugu Miyazaki; Yasuhito Higashiyama; Katsunori Yanagihara; Yoichi Hirakata; Kiyoyasu Fukushima; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

Review 4.  New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria.

Authors:  Mohammad J Nasiri; Mehri Haeili; Mona Ghazi; Hossein Goudarzi; Ali Pormohammad; Abbas A Imani Fooladi; Mohammad M Feizabadi
Journal:  Front Microbiol       Date:  2017-04-25       Impact factor: 5.640

5.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

6.  Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.

Authors:  L Rigouts; N Coeck; M Gumusboga; W B de Rijk; K J M Aung; M A Hossain; K Fissette; H L Rieder; C J Meehan; B C de Jong; A Van Deun
Journal:  J Antimicrob Chemother       Date:  2015-11-24       Impact factor: 5.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.